Abstract:Antiangiogenic therapy is widely administered in many cancers, and the antiangiogenic drug sorafenib offers moderate benefits in advanced hepatocellular carcinoma (HCC). However, antiangiogenic therapy can also lead to hypoxia-driven angiogenesis and immunosuppression in the tumor microenvironment (TME) and metastasis. Here, we report the synthesis and evaluation of NanoMnSor, a tumor-targeted, nanoparticle drug carrier that efficiently codelivers oxygen-generating MnO2 and sorafenib into HCC. We found that MnO2 not only alleviates hypoxia by catalyzing the decomposition of H2O2 to oxygen but also enhances pH/redox-responsive T1-weighted magnetic resonance imaging and drug-release properties upon decomposition into Mn2+ ions in the TME. Moreover, macrophages exposed to MnO2 displayed increased mRNA associated with the immunostimulatory M1 phenotype. We further show that NanoMnSor treatment leads to sorafenib-induced decrease in tumor vascularization and significantly suppresses primary tumor growth and distal metastasis, resulting in improved overall survival in a mouse orthotopic HCC model. Furthermore, NanoMnSor reprograms the immunosuppressive TME by reducing the hypoxia-induced tumor infiltration of tumor-associated macrophages, promoting macrophage polarization toward the immunostimulatory M1 phenotype, and increasing the number of CD8+ cytotoxic T cells in tumors, thereby augmenting the efficacy of anti-PD-1 antibody and whole-cell cancer vaccine immunotherapies. Our study demonstrates the potential of oxygen-generating nanoparticles to deliver antiangiogenic agents, efficiently modulate the hypoxic TME, and overcome hypoxia-driven drug resistance, thereby providing therapeutic benefit in cancer.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.0c08473?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.0c08473</a>.Profiles of hematologic parameters in mice treated with NanoMnSor; list of genes examined by RT-PCR and the primer sequences used; Fourier transform infrared analysis of lipid-coated MnO2 cores; Fourier transform infrared analysis of tumor-targeted NanoMnSor modified with SP94 peptides; a representative TEM image of NanoMnSor; oxygen generation from NanoMn or NanoMnSor in a H2O2 solution under pH 7.4 and 5.5; serum concentration profile of tumor-targeted MnO2-loaded PLGA NPs; tissue distribution of tumor-targeted MnO2-loaded PLGA NPs; representative immunofluorescence images of CD31, hypoxia, and TUNEL staining after NanoMnSor treatment; quantitative measures of hydroxyl radicals produced from the decomposition of hydrogen peroxide catalyzed by NanoMn; effects of hypoxia on M1 and M2 polarization in BMDMs; NanoMnSor-suppressed tumor growth in the orthotopic HCC model (<a class="ext-link" href="/doi/suppl/10.1021/acsami.0c08473/suppl_file/am0c08473_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

In Vitro and in Vivo Suppression of Hepatocellular Carcinoma Growth by Midkine-Antisense Oligonucleotide-Loaded Nanoparticles.

Toxicologic Evaluation of Repetitive 4-Week Intravenous Injections of Midkine Antisense Oligonucleotide Nanoliposomes in Rats

Single‐Vehicular Delivery of Antagomir and Small Molecules to Inhibit miR‐122 Function in Hepatocellular Carcinoma Cells by using “Smart” Mesoporous Silica Nanoparticles

Inhibitory Effect of EGFR Antisense Oligodeoxynucleotide on Human Hepatoma Cell Line.

Pharmacokinetics and Disposition of Heparin-Binding Growth Factor Midkine Antisense Oligonucleotide Nanoliposomes in Experimental Animal Species and Prediction of Human Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model

Ultra-small lipid nanoparticles encapsulating sorafenib and midkine-siRNA selectively-eradicate sorafenib-resistant hepatocellular carcinoma in vivo

siRNA targeting midkine inhibits gastric cancer cells growth and induces apoptosis involved caspase-3,8,9 activation and mitochondrial depolarization

Cell-Specific Expression of Artificial Micrornas Targeting Essential Genes Exhibit Potent Antitumor Effect on Hepatocellular Carcinoma Cells

Enhancing HepG2 Cell Apoptosis with a Combined Nanoparticle Delivery of Mir-128-3p Agomir and Oroxin B: A Novel Drug Delivery Approach Based on PI3K-AKT and VEGF Pathway Crosstalk

[Effects of Vascular Endothelial Growth Factor (VEGF) Antisense Oligodeoxynucleotide on Mrna and Expression of VEGF, Flt-1, and Kinase Insert Domain Containing Receptor and VEGF Excretion in Human Gallbladder Carcinoma Cells].

Effect of BZG-4000, a novel multi-targeted kinase inhibitor with potent anticancer activity, on a hepatocellular carcinoma xenograft model

Activity and Tissue Distribution of Antisense Oligonucleotide CT102 Encapsulated with Cytidinyl/Cationic Lipid against Hepatocellular Carcinoma

Ultrasound-Mediated Gene Therapy of Hepatocellular Carcinoma Using Pre-microRNA Plasmid-Loaded Nanodroplets

Chitosan Nanoparticles Inhibit the Growth of Human Hepatocellular Carcinoma Xenografts Through an Antiangiogenic Mechanism.

In Vitro and in Vivo Suppression of Hepatocellular Carcinoma Growth by Chitosan Nanoparticles

Modulation of Apoptosis, Tumorigenesity and Metastatic Potential with Antisense H-ras Oligodeoxynucleotides in a High Metastatic Tumor Model of Hepatoma: LCI-D20.

Nanoparticle Delivery of MnO 2 and Antiangiogenic Therapy to Overcome Hypoxia-Driven Tumor Escape and Suppress Hepatocellular Carcinoma

Use of Nanocurcumin to Inhibit Proliferation and Metastases of Hepatocellular Carcinoma Via NF-κB Mediated Matrix Metalloproteinase-9 Downregulation.

Effect of antisense oligodeoxynucelotide specific to ki-Ras gene on human gastric carcinoma cells and human vascular endothelial cells

Aurora Kinase Inhibitors Attached to Iron Oxide Nanoparticles Enhances Inhibition of the Growth of Liver Cancer Cells

Reducing Postoperative Recurrence of Early‐Stage Hepatocellular Carcinoma by a Wound‐Targeted Nanodrug